Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Takaichi Vows Cross-Party Talks on Social Security Reform
October 27, 2025
- Chuikyo Members Call for Revising Clozapine Fee Criteria to “Hospital-Based” Calculation
October 27, 2025
- Japan Panel OKs PCV20 as Routine Pneumococcal Shot for Elderly
October 27, 2025
- Japan Panel Backs NIP Use of High-Dose Flu Shot; Talks Continue on RSV Prevention
October 27, 2025
- Makoto Oniki Tapped as Head of LDP’s Health Division
October 27, 2025
- MHLW Outlines 4 Key Themes for 2026 Reform, Eyes OTC-Like Meds, CEA for Efficiency
October 24, 2025
- MHLW Sets Interim Nitrosamine Limit for Atomoxetine, 5 Generic Makers Launch Fresh Recalls
October 23, 2025
- New Health Minister Pledges to Strengthen Japan’s Drug Discovery Capabilities
October 23, 2025
- LDP’s Nagasaka Appointed Senior Vice Health Minister; Niki to Stay On
October 23, 2025
- Public-Private WG to Compile Industry Proposals on Drug Pricing Reforms at Next Session
October 23, 2025
- MHLW Orders Label Revisions for Amitiza, Shingrix, and More
October 23, 2025
- Takaichi Faces Tough Balancing Act on Healthcare, Nursing Reform
October 22, 2025
- LDP’s Takaichi Elected as Japan’s First Female Prime Minister
October 22, 2025
- LDP, Nippon Ishin to Form Coalition; OTC-Like Drug Copay Review Set for FY2025
October 21, 2025
- No Objections to Expanding Reimbursement Incentives for Biosimilars: Chuikyo
October 20, 2025
- Payers, Providers Clash over Fate of Fee Premiums for Generic Use
October 20, 2025
- MHLW Panel Launches Full Debate on Drug Coverage Reform; LLPs, Biologics, OTC-Like Meds in Focus
October 17, 2025
- GSK’s Blenrep, BMS’s Inrebic Absent from October Listing Roster
October 17, 2025
- Shionogi/Sage’s Depression Drug Up for MHLW Panel Review on Oct. 30
October 17, 2025
- SanBio’s Akuugo Nears Shipment with MHLW Panel Backing; Sakigake Tag OK’ed for Bayer Gene Therapies
October 17, 2025
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…